Claims for Patent: 8,598,219

Summary for Patent: 8,598,219

Title:	Liquid pharmaceutical formulations of palonosetron
Abstract:	The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
Inventor(s):	Calderari; Giorgio (Rancate, CH), Bonadeo; Daniele (Casalzuigno, IT), Cannella; Roberta (Varese, IT), Macciocchi; Alberto (Melide, CH), Miksztal; Andrew (Palo Alto, CA), Malefyt; Thomas (Carmel Valley, CA), Lee; Kathleen M (Palo Alto, CA), Panuccio; Carmine (Casnate con Bernat, IT)
Assignee:	Helsinn Healthcare SA (Lugano/Pazzallo, CH) Roche Palo Alto LLC (Palo Alto, CA)
Application Number:	13/901,437
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,598,219
Patent Claims:	1. A pharmaceutical single-use, unit-dose formulation for intravenous administration to a human to reduce the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising a 5 mL sterile aqueous isotonic solution, said solution comprising: palonosetron hydrochloride in an amount of 0.25 mg based on the weight of its free base; from 0.005 mg/mL to 1.0 mg/mL EDTA; and from 10 mg/mL to 80 mg/mL mannitol, wherein said formulation is stable at 24 months when stored at room temperature. 2. The pharmaceutical formulation of claim 1, wherein said EDTA is in an amount of 0.5 mg/mL. 3. The pharmaceutical formulation of claim 1, wherein said mannitol is in an amount of 41.5 mg/mL. 4. The pharmaceutical formulation of claim 1, wherein said solution further comprises a citrate buffer. 5. The pharmaceutical formulation of claim 4, wherein said citrate buffer is at a concentration of 20 millimolar. 6. The pharmaceutical formulation of claim 1, wherein said solution is buffered at a pH of 5.0 .+-.0.5. 7. The pharmaceutical formulation of claim 1, wherein said EDTA is in an amount of 0.5 mg/mL, wherein said mannitol is in an amount of 41.5 mg/mL, wherein said solution further comprises a citrate buffer at a concentration of 20 millimolar, and wherein said solution is buffered at a pH of 5.0 .+-.0.5. 8. A pharmaceutical single-use, unit-dose formulation for intravenous administration to a human to reduce the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising a 5 mL sterile aqueous isotonic solution, said solution comprising: palonosetron hydrochloride in an amount of 0.25 mg based on the weight of its free base; from 0.005 mg/mL to 1.0 mg/mL EDTA; and from 10 mg/mL to 80 mg/mL mannitol, wherein said formulation is stable at 18 months when stored at room temperature.